UK government backs all recommendations made following review of bias in medical devices Alongside recommendations on the use of AI devices in NHS healthcare, the review specifically calls for oximeter standards to be strengthened to ensure accuracy with darker skin tones.…
MHRA reviewing safety of asthma drug as Yellow Card reports increase The Medicines and Healthcare products Regulatory Agency is reviewing montelukast after there were 143 reports of psychiatric disorders associated with the drug in 2023.…
UK regulator recommends new safety measures for medicines containing pseudoephedrine Safety information for all medicines containing pseudoephedrine will be updated to make clear the risk of rare, but serious, side effects.…
Codeine linctus to be reclassified as a prescription-only medicine While codeine linctus is effective for long-term dry cough, the Medicines and Healthcare products Regulatory Agency said “misuse and abuse can have major health consequences”.…
Changing the culture of fluoroquinolone prescribing Despite repeated warnings about disabling and irreversible side effects from fluoroquinolones, prescribing of these broad-spectrum antibiotics remains “stubbornly stable”.…
DOACs to be analysed as part of genetic biobank scheme Patients who report adverse effects from direct oral anticoagulants to the Yellow Card scheme may be contacted to provide a blood sample, from which data will then be added to a biobank for researchers to analyse.…
More than £30m of illegal medicines seized by MHRA in 2023 The Medicines and Healthcare products Regulatory Agency says its support to online marketplaces led to the removal of more than half a million unregulated medicines and medical devices before they hit the UK market.…
MHRA says fluoroquinolones should be administered only when no other antibiotics are appropriate The Medicines and Healthcare products Regulatory Agency has issued new restrictions on fluoroquinolone use, following reports of serious adverse reactions in patients.…
Medicines regulator seeks expert advice on risk of developmental disorders in children fathered by men on valproate The Medicines and Healthcare products Regulatory Agency is to look again at evidence from a study evaluating the link between paternal valproate exposure and developmental disorders in children.…
FDA ‘evaluating regulatory action’ over link between GLP-1 receptor agonists and suicidal thoughts The US Food and Drug Administration said it had received reports of suicidal ideation in patients taking GLP-1 receptor agonists through its adverse events reporting system.…
